ArticleJournal of comparative physiology. B, Biochemical, systemic, and environmental physiology2026
Evaluation of anti-hyperglycemic, hepatic gene-modulatory and tissue-protective effects of curcumin, curcumin-loaded zeolitic imidazolate framework-8, and metformin in zebrafish (Danio rerio).
Article in Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Widely recognized for its translational relevance, the zebrafish (Danio rerio) is a validated model for evaluating antihyperglycemic agents. Nanocapsulation technologies have been proposed to enhance the bioefficacy of natural compounds such as curcumin (CUR), a bioactive compound derived from the turmeric plant (Curcuma longa) known for its anti-inflammatory and antioxidant properties. This study evaluated the effects of dietary curcumin, nano-formulated curcumin, and metformin, an oral antihyperglycemic medication commonly used to manage type 2 diabetes mellitus, on glycemic control, hepatic enzymatic activity, transcriptional levels of insulin a (insa) and phosphoenolpyruvate carboxykinase (pck), as well as intestinal and branchial histopathology in hyperglycemic adult zebrafish. Hyperglycemia was induced using dextrose monohydrate concurrently with the initiation of dietary interventions. Hyperglycemic fish were allocated to five groups receiving either an additive-free diet (Control + G), metformin (Met), curcumin (400 mg/kg; CUR400), or curcumin encapsulated in nanoscale zeolitic imidazolate framework-8 (ZIF-8) at 200 or 400 mg/kg (ZIFCUR200, ZIFCUR400) for 24 days. Non-hyperglycemic fish fed a standard diet served as negative controls (Control - G). Dietary curcumin at 400 mg/kg significantly improved glycemic control, modulated hepatic enzymatic activity, and downregulated pck expression in hyperglycemic zebrafish, while attenuating intestinal and branchial histopathological alterations compared with Control + G and ZIF-8-treated groups (p < 0.05). These effects were comparable to those observed with metformin as an anti-hyperglycemia drug. In contrast, nano-formulation of curcumin via ZIF-8 did not enhance its efficacy in glycemic regulation, insa expression, or tissue protection. Overall, curcumin demonstrated potential as a bioactive agent for mitigating hyperglycemia-induced physiological disturbances, underscoring its therapeutic applicability.
Indexed as
Identifiers
42191996What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.